Heart failure hospitalization — Research & Evidence

Q: What does the research say about Heart failure hospitalization?

The scientific consensus on Heart failure hospitalization is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for Heart failure hospitalization?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about Heart failure hospitalization?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Clinical questions in Heart failure hospitalization

Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.

Does beta-blockers vs placebo improve outcomes in Acute Inferior Myocardial Infarction?

Low Certainty+ Favors benefit

beta-blockers vs placebo · Myocardial Infarction Hospitalization

11 studies · 101,105 patients· 47 estimates

Does exenatide vs placebo improve All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent?

Low Certainty+ Favors benefit

exenatide vs placebo · All-Cause Mortality

5 studies · 44,256 patients· 5 estimates

Does eplerenone vs placebo improve outcomes in Acute Inferior Myocardial Infarction?

Low Certainty+ Favors benefit

eplerenone vs placebo · Myocardial Infarction Hospitalization

2 studies· 4 estimates

Does beta-blocker vs aspirin improve Myocardial Infarction Hospitalization in Myocardial Infarction?

Low Certainty− Favors harm

beta-blocker vs aspirin · Myocardial Infarction Hospitalization

2 studies · 60,354 patients· 2 estimates

Does tenecteplase vs placebo improve outcomes in ST segment elevation myocardial infarction?

Low Certainty− Favors harm

tenecteplase vs placebo · Myocardial Infarction Hospitalization

8 studies · 10,063 patients· 24 estimates

Does sacubitril vs valsartan improve outcomes in systemic right ventricular failure?

Low Certainty− Favors harm

sacubitril vs valsartan · Myocardial Infarction Hospitalization

2 studies · 40 patients· 13 estimates

Evidence brief: Heart failure hospitalization

Heart failure hospitalization (also known as ADHF, acute heart failure, HF admission). Acute decompensated HF and hospitalization outcomes

Synapse tracks 6 specific clinical questions in Heart failure hospitalization, each synthesized independently from its own trial evidence. They include: "Does beta-blockers vs placebo improve outcomes in Acute Inferior Myocardial Infarction?"; "Does exenatide vs placebo improve All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent?"; "Does eplerenone vs placebo improve outcomes in Acute Inferior Myocardial Infarction?"; "Does beta-blocker vs aspirin improve Myocardial Infarction Hospitalization in Myocardial Infarction?"; "Does tenecteplase vs placebo improve outcomes in ST segment elevation myocardial infarction?".

As of 2026-06-25, the scientific consensus on Heart failure hospitalization is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on Heart failure hospitalization. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a307b42209bc31dca334.

Deterministic synthesis from Synapse's enriched corpus — 282 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for Heart failure hospitalization?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest Heart failure hospitalization research

Explore every Heart failure hospitalization paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search Heart failure hospitalization papers